Company intelligence / Profile preview

Lumea

Lehi, Utah, United States

Ownership: Private
Development stage: Other

Overview

Lumea’s platform delivers measurable clinical improvements: up to 50% reduction in sign-out time, 9.3% increase in cancer detection rates, 76% lab processing time reduction, and substantial improvements in biopsy quality; its technology is validated by adoption in top US hospitals and large urology/derm/GI groups.

Therapeutic areas: OncologyOther
Modalities: DeviceSoftwareAI augmentation
Industry: Pathology

Partnerships

Partnered with major US urology, gastroenterology, dermatology practices, hospital networks, and pharmaceutical R&D organizationsWorks with AI companies and molecular testing organizations to expand its capabilities

Beyond the preview

Go deeper on Lumea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumea.

Explore the full profile